COMMUNIQUÉS West-GlobeNewswire

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

07/11/2024 - 16:00

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well [...]

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

07/11/2024 - 16:00

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest [...]

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

07/11/2024 - 16:00

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda ® demonstrated promising activity with an overall response rate of 55% [...]

Aummune Announces Results from Phase 1 Trial of its Novel AM003 Immunotherapy for the Treatment of Solid Tumors

07/11/2024 - 16:00

Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting AM003 is a first-in-class functional oligonucleotide in development for the treatment of solid tumors First –in-human, monotherapy dose- [...]

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

07/11/2024 - 13:30

– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 [...]

Quotient Therapeutics Appoints Sir Mene Pangalos, Ph.D. to Board of Directors

07/11/2024 - 13:30

Sir Mene Pangalos, Ph.D., joins Geoffrey von Maltzahn, Ph.D., Noubar Afeyan, Ph.D., Professor Sir Mike Stratton, and Michael Severino, M.D., on the board CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quotient [...]

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07/11/2024 - 13:30

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on track to initiate study [...]

Tilray Launches "Men's Health on Tap" Podcast: Acclaimed Doctors Engage in Empowering Discussions and Break Down Stigmas Around Men's Health Topics

07/11/2024 - 13:30

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a lifestyle and consumer packaged goods company, announces the launch of "Men's Health on Tap," a new podcast series hosted [...]

iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually

07/11/2024 - 13:30

WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

07/11/2024 - 13:30

Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential benefits of balanced [...]

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

07/11/2024 - 13:30

Zevra’s MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty’s portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience’s portfolio of 60-plus [...]

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

07/11/2024 - 13:30

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07/11/2024 - 13:30

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE, Nov. 07, 2024 ( [...]

Vericel Reports Third Quarter 2024 Financial Results

07/11/2024 - 13:55

Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference [...]

Cassava Sciences Reports Q3 2024 Financial and Operating Results

07/11/2024 - 13:55

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast [...]

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

07/11/2024 - 14:00

Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increase Over 143,000 prescriptions filled for VOQUEZNA ® (vonoprazan [...]

Healthy and Beauty Synergies: MEDIROM Healthcare Technologies and SBC Medical Group Holdings Announce Business Alliance

07/11/2024 - 14:00

TOKYO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announced a business alliance with SBC Medical Group Holdings Incorporated (Nasdaq: SBC) a global owner, operator and provider [...]

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

07/11/2024 - 14:00

GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global leader in the discovery, development, manufacturing, and delivery of [...]

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

07/11/2024 - 14:00

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov [...]